Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Principles of Drug Action01:24

Principles of Drug Action

Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloids.

Chirality·2022
Same author

Identification of unprecedented ATP-competitive choline kinase inhibitors.

Bioorganic & medicinal chemistry letters·2021
Same author

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic <i>NTRK</i> targeted cancer therapies.

ESMO open·2020
Same author

Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

Journal of medicinal chemistry·2019
Same author

Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.

ACS medicinal chemistry letters·2019
Same author

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.

Molecular cancer therapeutics·2017

Related Experiment Video

Updated: May 21, 2026

Determining the Chemical Composition of Corrosion Inhibitor/Metal Interfaces with XPS: Minimizing Post Immersion Oxidation
07:44

Determining the Chemical Composition of Corrosion Inhibitor/Metal Interfaces with XPS: Minimizing Post Immersion Oxidation

Published on: March 15, 2017

ALK Inhibitors, a Pharmaceutical Perspective.

Elena Ardini1, Arturo Galvani

  • 1Department of Cell Biology, Oncology, Nerviano Medical Sciences Milan, Italy.

Frontiers in Oncology
|June 2, 2012
PubMed
Summary
This summary is machine-generated.

Crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, offers personalized medicine for non-small-cell lung cancer. Acquired resistance to this targeted therapy emerges through ALK mutations and independent mechanisms, necessitating new treatment strategies.

Keywords:
ALCLALKIMTNSCLCcrizotinibinhibitorneuroblastomaresistance

More Related Videos

Optimized Procedure for Determining the Adsorption of Phosphonates onto Granular Ferric Hydroxide using a Miniaturized Phosphorus Determination Method
08:21

Optimized Procedure for Determining the Adsorption of Phosphonates onto Granular Ferric Hydroxide using a Miniaturized Phosphorus Determination Method

Published on: May 18, 2018

Related Experiment Videos

Last Updated: May 21, 2026

Determining the Chemical Composition of Corrosion Inhibitor/Metal Interfaces with XPS: Minimizing Post Immersion Oxidation
07:44

Determining the Chemical Composition of Corrosion Inhibitor/Metal Interfaces with XPS: Minimizing Post Immersion Oxidation

Published on: March 15, 2017

Optimized Procedure for Determining the Adsorption of Phosphonates onto Granular Ferric Hydroxide using a Miniaturized Phosphorus Determination Method
08:21

Optimized Procedure for Determining the Adsorption of Phosphonates onto Granular Ferric Hydroxide using a Miniaturized Phosphorus Determination Method

Published on: May 18, 2018

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Anaplastic lymphoma kinase (ALK) identified as a therapeutic target in non-small-cell lung cancer (NSCLC) in 2007.
  • Rapid approval of crizotinib, an ALK inhibitor, marked a significant advancement in personalized cancer therapy.
  • Development of companion diagnostics for patient selection enabled targeted treatment strategies.

Purpose of the Study:

  • To discuss factors contributing to the rapid approval of crizotinib.
  • To describe the mechanisms of acquired resistance to crizotinib.
  • To review second-generation ALK inhibitors in development.

Main Methods:

  • Literature review of ALK inhibitors in NSCLC treatment.
  • Analysis of clinical trial data regarding crizotinib efficacy and resistance.
  • Exploration of emerging resistance pathways, including ALK-independent mechanisms.

Main Results:

  • Crizotinib demonstrated clinical efficacy, leading to FDA approval for ALK-positive NSCLC.
  • Acquired resistance to crizotinib has been observed, primarily due to secondary ALK point mutations.
  • ALK-independent resistance mechanisms are also emerging and require further elucidation.

Conclusions:

  • The rapid development and approval of crizotinib exemplify personalized medicine in oncology.
  • Understanding resistance mechanisms is crucial for developing next-generation therapies.
  • Continued research into ALK-independent resistance pathways is essential for overcoming treatment limitations.